Loading stock data…
Caris Life Sciences (CAI)
$18.32-0.18 (-0.97%)
Market ClosedLast close Jun 29
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Caris Life Sciences, Inc. in the Healthcare sector is trading at $18.32 with a market capitalization of $5.2B. Wall Street consensus targets $27.83 (12 analysts), implying a +51.9% move over the next 12 months. The stock is currently near its 52-week low of $14.19, remaining 21.6% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +51.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $216.17M↓ | $292.89M↑ | $216.83M↑ | $181.40M↑ | $120.92M |
| Gross Profit | $141.35M↓ | $220.91M↑ | $147.51M↑ | $113.69M↑ | $57.06M |
| Operating Income | $5.28M↓ | $88.41M↑ | $32.64M↑ | -$17.99M↑ | -$57.95M |
| Net Income | -$510,000↓ | $81.96M↑ | $24.32M↑ | -$71.79M↑ | -$102.58M |
Peer Comparison
JNJUNHPFE
Fundamentals
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.15B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
5.73%
Volume
Today's trading volume
3.77M
Recent News
Is Caris Life Sciences, Inc. (CAI) A Good Stock To Buy Now?
Is CAI a good stock to buy? We came across a bullish thesis on Caris Life Sciences, Inc. on InfoArb Sheets’s Substack. In this article, we will summarize the bulls’ thesis on CAI. Caris Life Sciences, Inc.’s share was trading at $18.47 as of June 18th. CAI’s forward P/E was 46.95 according to Yahoo Finance. Caris Life […]
Caris Life Sciences (CAI) Announces $100M Share Repurchase Program
Caris Life Sciences Inc. (NASDAQ:CAI) is one of the best new stocks to buy with the huge upside potential. On June 8, Caris Life Sciences announced that its Board of Directors authorized a program to repurchase up to $100 million of its outstanding common stock. As a prominent precision medicine and AI TechBio company, Caris […]
Caris Life Sciences Announces That It’s Dual Listing on NYSE Texas
null
You’ve Likely Never Heard of Caris Life Sciences Stock. Billionaire Stanley Druckenmiller Has – and He Likes What He Sees.
Caris Life Sciences just earned a $33.87 million vote of confidence from Stanley Druckenmiller, and most people completely missed it.
Caris Life Sciences Advances Precision Oncology As Shares Trade Below Targets
Caris Life Sciences (NasdaqGS:CAI) published a pivotal study on its Caris Lookback Program confirming its effectiveness in finding patients eligible for newly approved targeted therapies. The company released new evidence that Whole Exome Sequencing supports more robust tumor mutational burden assessment for immunotherapy eligibility. Caris also recently launched Caris MI Clarity, an AI driven test aimed at assessing breast cancer recurrence risk. For investors watching precision oncology,...